SK Plasma said that it has signed a contract with Khairi S.A., a South American pharmaceutical sales company, to export 38.4 billion won ($31.8 million) of blood products.

SK Plasma will export 38.4 billion won worth of blood products to the Latin American market through Khairi S.A., a local pharmaceutical sales company.
SK Plasma will export 38.4 billion won worth of blood products to the Latin American market through Khairi S.A., a local pharmaceutical sales company.

Under the accord, Khairi will have the right to supply SK Plasma's blood products, such as LIV-r Inj. and albumin, to eight countries -- Argentina, the Dominican Republic, Venezuela, Guatemala, Bolivia, Chile, Uruguay, and Paraguay.

The two companies will jointly carry out the licensing process required for delivery in each country and plan to start supplying them as early as 2024.

Based on the contract, SK Plasma aims to develop the South American market as a major export area.

This is the second time the company has successfully exported finished blood products this year, following a supply contract to the Middle East on Jan. 6.

"Most South American countries do not have blood product development and manufacturing infrastructure, although the region's blood product market is estimated at 1.5 trillion won annually," SK Plasma CEO Kim Yun-ho said. "Based on our products’ superior quality, SK Plasma will strive to create additional opportunities by exporting CMO and plant technology."

Copyright © KBR Unauthorized reproduction, redistribution prohibited